Janux Therapeutics, Inc. Stock Price, News & Analysis

Janux Therapeutics (NASDAQ: JANX) has reported its Q1 2025 financial results and provided key business updates. The company has initiated Phase 1b expansion studies for JANX007 in taxane-naïve mCRPC patients, with updated results showing a median radiographic progression-free survival (rPFS) of 7.5 months across 16 patients. For patients treated at higher doses (6mg and 9mg), the median rPFS reached 7.9 months. The company plans to initiate three additional Phase 1b expansion studies for JANX007 in different mCRPC patient populations. Financially, Janux maintains a strong position with $1.01 billion in cash and investments as of March 31, 2025. The company reported R&D expenses of $25.1 million and a net loss of $23.5 million for Q1 2025. Updates on both JANX007 and JANX008 clinical programs are expected in H2 2025, and the company plans to host an R&D Day in mid-2025 to showcase its preclinical pipeline.

Janux Therapeutics (NASDAQ: JANX) has initiated Phase 1b expansion studies for JANX007 in metastatic castration-resistant prostate cancer (mCRPC) patients. Updated data from Phase 1a dose escalation in 16 patients showed promising results with a median radiographic progression-free survival (rPFS) of 7.5 months across all patients, and 7.9 months for those treated at 6mg and 9mg target doses. The 6-month rPFS rates were 65% for all patients and 78% for the higher dose groups. The company plans to conduct four Phase 1b expansion studies, including evaluations of JANX007 as monotherapy and in combination with other treatments. Additional data from JANX007 and JANX008 programs will be presented in H2 2025, with an R&D Day planned for mid-2025 to showcase preclinical pipeline advancements.

Janux Therapeutics (NASDAQ: JANX) reported its Q4 and full year 2024 financial results, highlighting significant clinical progress and strong financial position. The company presented positive Phase 1 trial data for PSMA-TRACTr JANX007 in prostate cancer, showing impressive results including 100% PSA50 decline rates and 50% objective response rate in treated patients.

Financial highlights include $1.03 billion in cash and investments as of December 31, 2024, bolstered by a $402.5 million capital raise in December 2024. The company reported increased R&D expenses of $68.4 million and G&A expenses of $41.0 million for 2024, with a net loss of $69.0 million.

Clinical progress continues with ongoing enrollment for both JANX007 and JANX008 trials, with updates anticipated in 2025 along with an R&D Day to discuss new programs.

Janux Therapeutics (NASDAQ: JANX) has promoted Dr. Zachariah McIver to Chief Medical Officer. Dr. McIver, a physician-scientist with over 20 years of clinical research experience, previously served as Amgen's Executive Medical Director for more than 4 years, where he led BiTE assets development across multiple cancer types.

The company is developing immunotherapies through its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Their clinical pipeline includes JANX007, a TRACTr targeting PSMA in Phase 1 trials for mCRPC patients, and JANX008, a TRACTr targeting EGFR in Phase 1 trials for multiple solid cancers including colorectal, head and neck, lung, renal, and breast cancers.

Janux Therapeutics (NASDAQ: JANX) has successfully closed its previously announced public offering, raising $402.5 million in gross proceeds. The offering included 6,150,793 shares of common stock at $63.00 per share and 238,095 pre-funded warrants at $62.999 per warrant. The underwriters exercised their full option to purchase an additional 833,333 shares.

The offering was managed by several investment banks, including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair as joint book-running managers. The company plans to use the proceeds to advance its clinical development pipeline and for general corporate purposes.

Janux Therapeutics (NASDAQ: JANX) has announced the pricing of a $350.0 million public offering, consisting of 5,317,460 shares of common stock at $63.00 per share and 238,095 pre-funded warrants at $62.999 per warrant. The company has granted underwriters a 30-day option to purchase up to 833,333 additional shares.

The offering, expected to close around December 6, 2024, is being managed by multiple investment banks including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair as joint book-running managers. The proceeds will be used to advance clinical development of Janux's internal product pipeline and for general corporate purposes.

Janux Therapeutics (NASDAQ: JANX), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $300.0 million of common stock shares or pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $45.0 million of shares.

The offering will be managed by multiple joint book-running managers including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair. Janux intends to use the proceeds to advance clinical development of its internal product pipeline and for general corporate purposes. The securities will be offered through a Registration Statement on Form S-3 filed with the SEC.

Janux Therapeutics (NASDAQ: JANX) announced positive interim clinical data for JANX007 in metastatic castration-resistant prostate cancer (mCRPC). In 16 heavily pre-treated patients, JANX007 showed remarkable efficacy with 100% achieving PSA50 declines, 63% reaching PSA90 declines, and 31% achieving PSA99 declines. The treatment demonstrated 50% objective response rate and was well-tolerated with primarily grade 1 and 2 side effects. Based on these results, Janux has selected doses for Phase 1b expansion trials targeting pre-PLUVICTO® 2L/3L patients, with another update expected in 2025.

Janux Therapeutics (NASDAQ: JANX) announced a virtual event scheduled for December 2, 2024, at 4:30 PM ET to discuss updated clinical data from JANX007's Phase 1a dose escalation trial in metastatic castration-resistant prostate cancer (mCRPC) patients. The company will also reveal doses selected for Phase 1b expansion studies. The event will feature CEO David Campbell and include a Q&A session. JANX007 is the company's first clinical TRACTr candidate targeting PSMA, while their second candidate, JANX008, targets EGFR for multiple solid cancers.